Trials / Completed
CompletedNCT03843632
Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
An Open-Label, Multicenter, Single-arm Study to Evaluate the Immunogenicity of VARIVAX™ in Healthy Russian Individuals 12 Months of Age and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 12 Months – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study was to evaluate the immunogenicity and safety of VARIVAX™ vaccine in healthy Russian children, adolescents, and adults. No formal hypothesis was tested.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VARIVAX™ | VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants). |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2020-06-19
- Completion
- 2020-06-19
- First posted
- 2019-02-18
- Last updated
- 2021-04-06
- Results posted
- 2021-04-06
Locations
5 sites across 1 country: Russia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03843632. Inclusion in this directory is not an endorsement.